Mesothelin CAR-T cell therapy (Shenzhen BinDeBio)

N/A

Report date: 2024/12/23 15:36:25

Base Information

Drug NameMesothelin CAR-T cell therapy (Shenzhen BinDeBio)
Drug Alias NameCART-meso cells - Shenzhen BinDeBio
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsPancreatic NeoplasmsStomach Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShenzhen Bindebio Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShenzhen Bindebio LtdJiangsu Provincial People'S Hospital (The First Affiliated Hospital Of Nanjing Medical University)
Inactive CompaniesN/A
Active IndicationsPancreatic NeoplasmsStomach Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A